Publications in collaboration with researchers from Université Catholique de Louvain (7)

2021

  1. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

    ESMO Open, Vol. 6, Núm. 5

  2. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: Post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

    Japanese Journal of Clinical Oncology, Vol. 51, Núm. 8, pp. 1287-1297

  3. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study

    European Urology, Vol. 80, Núm. 4, pp. 497-506

2020

  1. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1513-1525

2019

  1. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

    New England Journal of Medicine, Vol. 381, Núm. 26, pp. 2506-2518

2015

  1. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: Introducing the prostate cancer consortium in Europe

    European Urology, Vol. 67, Núm. 5, pp. 904-912

2013

  1. Larotaxel with cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: A randomized, active-controlled, phase III trial (CILAB)

    Oncology (Switzerland), Vol. 85, Núm. 4, pp. 208-215